Sonoma Pharmaceuticals Inc (SNOA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has a cash flow conversion efficiency ratio of -0.223x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-764.00K) by net assets ($3.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sonoma Pharmaceuticals Inc (SNOA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Sonoma Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sonoma Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telo Genomics Corp
V:TELO
|
11.261x |
|
KWG Group Holdings Limited
F:KOU
|
0.049x |
|
Zephyr Minerals Ltd
V:ZFR
|
0.006x |
|
DMD Digital Health Connections Group Inc
NASDAQ:APTOF
|
0.215x |
|
Trucknet Enterprise Ltd
TA:TRAN
|
N/A |
|
Applied DNA Sciences Inc
NASDAQ:APDN
|
-0.403x |
|
ASOS Plc
LSE:ASC
|
0.700x |
|
Prima Alloy Steel Universal
JK:PRAS
|
0.006x |
Annual Cash Flow Conversion Efficiency for Sonoma Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sonoma Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see SNOA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $4.41 Million | $-88.00K | -0.020x | +94.89% |
| 2024-03-31 | $6.14 Million | $-2.40 Million | -0.391x | +49.33% |
| 2023-03-31 | $7.98 Million | $-6.15 Million | -0.771x | -57.89% |
| 2022-03-31 | $8.70 Million | $-4.25 Million | -0.488x | +22.45% |
| 2021-03-31 | $5.36 Million | $-3.38 Million | -0.630x | +22.84% |
| 2020-03-31 | $5.62 Million | $-4.59 Million | -0.816x | +26.92% |
| 2019-03-31 | $10.49 Million | $-11.72 Million | -1.117x | -37.63% |
| 2018-03-31 | $15.33 Million | $-12.44 Million | -0.812x | -112.98% |
| 2017-03-31 | $21.43 Million | $-8.17 Million | -0.381x | +55.82% |
| 2016-03-31 | $10.14 Million | $-8.75 Million | -0.863x | -55.32% |
| 2015-03-31 | $12.05 Million | $-6.69 Million | -0.555x | -36.99% |
| 2014-03-31 | $12.06 Million | $-4.89 Million | -0.405x | -243.85% |
| 2013-03-31 | $4.08 Million | $1.15 Million | 0.282x | -93.93% |
| 2012-03-31 | $-868.00K | $-4.03 Million | 4.645x | +278.40% |
| 2011-03-31 | $1.70 Million | $-4.43 Million | -2.604x | -176.30% |
| 2010-03-31 | $7.04 Million | $-6.64 Million | -0.942x | +87.30% |
| 2009-03-31 | $2.27 Million | $-16.83 Million | -7.418x | -556.02% |
| 2008-03-31 | $15.43 Million | $-17.45 Million | -1.131x | +6.81% |
| 2007-03-31 | $14.90 Million | $-18.08 Million | -1.213x | +56.61% |
| 2006-03-31 | $7.34 Million | $-20.52 Million | -2.796x | +54.50% |
| 2005-03-31 | $2.20 Million | $-13.53 Million | -6.146x | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more